Protocol Ledger

NCT05978739 · Phase II · COMPLETED

Evaluating Different Doses of Orelabrutinib in MCL

Interventional Phase II clinical trial protocol NCT05978739 sponsored by InnoCare Pharma in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-08-18 Enrollment: 40 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05978739
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)40 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05978739
Protocol FieldVerified Registry Value
NCT IdentifierNCT05978739
Consolidated Lead SponsorInnoCare Pharma
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment40 participants (ACTUAL)
Registered Start Date2023-08-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI